(Q39474116)

English

Detrimental effects of melanocortin-1 receptor (MC1R) variants on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors

scientific article published on 19 August 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Detrimental effects of melanocortin-1 receptor (MC1R) variants on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

metastatic melanoma

1 reference

based on heuristic

inferred from title

Stefania Tommasi

8

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

object named as

Anna Ferretta

3

0 references

Nicola Bartolomeo

object named as

Nicola Bartolomeo

4

0 references

object named as

Stefania Guida

10

0 references

author name string

Michele Guida

1

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Sabino Strippoli

2

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Letizia Porcelli

5

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Immacolata Maida

6

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Amalia Azzariti

7

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Claudia Grieco

9

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Anna Albano

11

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Vito Lorusso

12

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Gabriella Guida

13

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

publication date

19 August 2016

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Pigment Cell & Melanoma Research

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

679-687

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

alpha-MSH tripeptide analogs activate the melanocortin 1 receptor and reduce UV-induced DNA damage in human melanocytes

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

A method and server for predicting damaging missense mutations

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

alpha-Melanocyte-stimulating hormone protects from ultraviolet radiation-induced apoptosis and DNA damage

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

MC1R is a potent regulator of PTEN after UV exposure in melanocytes

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

Predicting the functional effect of amino acid substitutions and indels

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

Melanocortin 1 receptor regulates melanoma cell migration by controlling syndecan-2 expression.

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

Inherited variants in the MC1R gene and survival from cutaneous melanoma: a BioGenoMEL study

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

Interactive effects of MC1R and OCA2 on melanoma risk phenotypes

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification.

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

MC1R variants increase risk of melanomas harboring BRAF mutations.

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

Effect of resveratrol on mitochondrial function: implications in parkin-associated familiar Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

MC1R, the cAMP pathway, and the response to solar UV: extending the horizon beyond pigmentation

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

Variants of the melanocortin-1 receptor: do they matter clinically?

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

Melanocortin 1 receptor mutations impact differentially on signalling to the cAMP and the ERK mitogen-activated protein kinase pathways

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

Functional status and relationships of melanocortin 1 receptor signaling to the cAMP and extracellular signal-regulated protein kinases 1 and 2 pathways in human melanoma cells.

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

Melanocortin 1 receptor genotype: an important determinant of the damage response of melanocytes to ultraviolet radiation.

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

Alpha-melanocyte-stimulating hormone suppresses oxidative stress through a p53-mediated signaling pathway in human melanocytes.

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

Prostate cancer risk: associations with ultraviolet radiation, tyrosinase and melanocortin-1 receptor genotypes

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

MC1R and cAMP signaling inhibit cdc25B activity and delay cell cycle progression in melanoma cells

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

Simultaneous purifying selection on the ancestral MC1R allele and positive selection on the melanoma-risk allele V60L in south Europeans.

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

Human melanocytes expressing MC1R variant alleles show impaired activation of multiple signaling pathways.

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

Human melanocortin 1 receptor (MC1R) gene variants alter melanoma cell growth and adhesion to extracellular matrix

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

Association between the germline MC1R variants and somatic BRAF/NRAS mutations in melanoma tumors.

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

ERK1/2 and p38α/β signaling in tumor cell quiescence: opportunities to control dormant residual disease

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

Resistance to BRAF-targeted therapy in melanoma

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

Inherited variation at MC1R and histological characteristics of primary melanoma

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

Inherited variation at MC1R and ASIP and association with melanoma-specific survival

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

Cyclic AMP inhibits p38 activation via CREB-induced dynein light chain.

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12516

21 January 2018

Identifiers

10.1111/PCMR.12516

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

release_cjpzckuhirdpzcieuvufct22qu

1 reference

https://api.fatcat.wiki/v0/release/cjpzckuhirdpzcieuvufct22qu

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39474116&oldid=1839358018"